

Ivy Foundation

Early Phase Clinical Trials Consortium

PRINCIPAL INVESTIGATOR

Michael Prados, MD
UCSF
Project Leader



Consortium Participants: UCSF, MGH/Harvard, University of Utah Cancer Center, Memorial Sloan-Kettering, UCLA, MD Anderson, and Dana-Farber Cancer Institute

CENTRAL HYPOTHESIS

“Personalized” treatment of patients will improve outcome

INITIAL SPECIFIC AIMS

- 1: Create the Consortium
- 2: Conduct highly efficient clinical trials
- 3: Create a unique tumor tissue repository

PROGRESS REPORT

ALL OF THE AIMS ARE COMPLETE AND ONGOING

Two Completed Clinical Trials:

- 1: Study of XL765 and XL147 Administered as Single Agents to Subjects with Recurrent Glioblastoma
- 2: A Phase 2 Study of Orally Administered PLX3397 in Patients With recurrent Glioblastoma

Three Ongoing Clinical Trials:

- 1: A phase II study of BKM120 for patients with recurrent Glioblastoma and activated PI3K pathway
- 2: A feasibility trial using tissue-based molecularly characterized features of individualized patient tumors to select treatment
- 3: A Phase II study of Pembrolizumab (MK 3475) with and without Bevacizumab for Recurrent Glioblastoma

New Protocols in Development:

- 1: A phase 1b study of DCC-2701 in patients with recurrent Glioblastoma
- 2: A phase 2 study of the efficacy of a tissue-based, precision medicine strategy in recurrent glioblastoma

Virtual Tissue/Imaging/Genomics Bank: More than 1200 cases enrolled with a brand new effort to include important MRI imaging information for each patient, as well as genomic data, linking tumor information with clinical outcome and imaging information.



THE BEN AND CATHERINE
IVY FOUNDATION